Skip to main content

Table 2 Cost and disability weight inputs for the high burden countries analyzed, US$ 2013a

From: Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

Parameter Country
Estonia Russia South Africa Peru China Philippines India
Cost of treatment per month, US$ [source]
 Cost of BR (intensive) 141 [20, 25] 273 [18] 167 [25, 36] 149 [22] 78 [23] 134 [25] 95 [37]
 Cost of BR (continuation) 78 [20;25] 183 [18] 49 [25, 36] 71 [22] 26 [23] 88 [25] 40 [37]
Cost of monitoring per month, US$ [source]
 Bedaquiline + BR Intensive phase 109 [20] 122 [19] 81 [26] 81 [21] 63 [23] 65b 44 [38, 39]
Continuation phase 98 [20] 94 [19] 64 [26] 70 [21] 55 [23] 595b 36 [38, 39]
 BR only Intensive phase 101 [20] 100 [19] 65 [26] 68 [21] 60 [23] 59b 43 [38, 39]
Continuation phase 90 [20] 72 [19] 48 [26] 57 [21] 52 [23] 53b 35 [38, 39]
Cost of inpatient and outpatient care, US$ [source]
 Cost of hospitalization for initial MDR-TB per day 268 [24] 231 [18] 84 [26] 55 [21] 38 [24] 20 [24] 16 [30]
 Cost of outpatient care for initial MDR-TB No. of consultation per month (mean)/unit cost 1/41 [24] 1/36 [24] 1/17 [26] 1/11 [21] 1/9 [24] 1/6 [24] 1/3 [30]
No. of TB nurse home visits per month (mean)/unit cost 28/1 [24] 28/0 [24] 28/NA [26] 28/NA [21] 28/NA [24] 28/NA [24] 28/NA [30]
Disability weights (mean) by health state for all countries analyzed
 Active TB 0.331 [16]
 Culture converted TB (first year) 0.170 [16]
 Culture converted TB (subsequent year) 0.170 [16]
 Lost to follow-up 0.331 (Assumed equal to the active MDR-TB state)
 Treatment complete and cured 0 (Assumed equal to the general population [41])
 Death 1
  1. BR background regimen, MDR-TB multidrug-resistant tuberculosis, NA Not available, US United States
  2. aAll costs have been converted and inflated to 2013 US$
  3. bSOURCE: local hospital